Kazia Therapeutics (KZIA) shares fell more than 6% in pre-market trading Tuesday after the company said it was considering options for its drug candidate paxalisib after the US Food and Drug Administration discouraged an accelerated approval process for the potential glioblastoma treatment.
The company said a July study of the drug showed "clinically meaningful improvement" for overall survival compared to the standard of care in the treatment of brain cancer. The FDA said the results could be considered to support a standard approval process and aligned with the company on designing a phase 3 study, the company said.
The company said it is testing paxalisib for several other indications and will present an outline for a path forward on the drug by the end of January.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。